<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819347</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-3BNC117_202</org_study_id>
    <nct_id>NCT04819347</nct_id>
  </id_info>
  <brief_title>Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection</brief_title>
  <official_title>The Phase 2, Two Arms, One Site, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection After Analytical Treatment Interruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frontier Biotechnologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frontier Biotechnologies Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study to evaluate the safety and tolerability of combination therapy with&#xD;
      Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and&#xD;
      explore the potential of viral suppression and viral reservoir clearance after analytical&#xD;
      treatment interruption (ATI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, one site study, in which a total of 24 HIV-1 subjects who are&#xD;
      virologically suppressed and stable on daily oral combination antiretroviral therapy will be&#xD;
      enrolled.&#xD;
&#xD;
      All eligible patients will be switched from daily oral combination antiretroviral regimen to&#xD;
      treatment of ABT and 3BNC117 for 14 weeks. There is a two-week overlap of the baseline oral&#xD;
      antiretroviral therapy and the ABT-3BNC117 combination regimen at the beginning of the study&#xD;
      treatment, and then the oral ART will be interrupted.&#xD;
&#xD;
      The patients will be monitored for viral rebound every two or four weeks following initiation&#xD;
      of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virological&#xD;
      rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive&#xD;
      test.&#xD;
&#xD;
      Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants (with sustained viral suppression at week 14) with HIV-1 RNA &lt; 50 copies/mL at Week 26 (24 weeks after ATI)</measure>
    <time_frame>Week 26</time_frame>
    <description>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Week 26.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time to virologic rebound (HIV-1 RNA≥200 copies/mL) after ATI</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Mean time to virologic rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants without experiencing virologic rebound (HIV-1 RNA&lt;200 copies/mL) at Week 26 (24 weeks after ATI).</measure>
    <time_frame>Week 26</time_frame>
    <description>Proportion of participants without experiencing virologic rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Week 26 (24 weeks after ATI).</measure>
    <time_frame>Week 26</time_frame>
    <description>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD4 cell count after ATI</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Mean change in CD4 cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD4/CD8 ration after ATI</measure>
    <time_frame>up to 48weeks</time_frame>
    <description>Mean change in CD4/CD8 ration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of emergence of new resistance mutations after virologic rebound</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Frequency of emergence of new resistance mutations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to achieving HIV-1 RNA &lt; 50 copies/mL after experiencing virologic rebound</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Mean time to achieving HIV-1 RNA &lt; 50 copies/mL after experiencing virologic rebound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Early treatment of infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA &lt;50 copies/mL for at least 12 months.&#xD;
Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic period of infection treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA &lt;50 copies/mL for at least 12 months.&#xD;
Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuvirtide</intervention_name>
    <description>Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)</description>
    <arm_group_label>Chronic period of infection treatment</arm_group_label>
    <arm_group_label>Early treatment of infection</arm_group_label>
    <other_name>ABT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3BNC117</intervention_name>
    <description>Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.</description>
    <arm_group_label>Chronic period of infection treatment</arm_group_label>
    <arm_group_label>Early treatment of infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, age ≥18 years&#xD;
&#xD;
          2. For cohort 1: HIV-1 infected subjects initiated a stable combination antiretroviral&#xD;
             therapy (ART) within 6 months of primary HIV infection (PHI), having the document&#xD;
             evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy within&#xD;
             6 months of PHI.&#xD;
&#xD;
             For cohort 2: Chronically HIV-1 infected subjects initiated a stable combination&#xD;
             antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), having the&#xD;
             document evidence of initial diagnosis of HIV-1 infection and initiation of ART&#xD;
             therapy after 6 months of PHI.&#xD;
&#xD;
          3. Plasma HIV-1 RNA &lt;50 copies/mL for at least 12 months prior to Screening Visit. An&#xD;
             exception for a recorded HIV-1 RNA &quot;blip&quot; (e.g., transient HIV-1 RNA &gt;50 copies/mL)&#xD;
             can be considered.&#xD;
&#xD;
          4. Plasma HIV-1 RNA &lt;20 copies/mL at Screening Visit.&#xD;
&#xD;
          5. CD4 cell count &gt;500 cells/µL.&#xD;
&#xD;
          6. Laboratory values at Screening of:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥0.75×10∧9/L;&#xD;
&#xD;
               2. Hemoglobin (Hb) ≥105 g/L (male) or ≥95 g/L (female);&#xD;
&#xD;
               3. Platelets ≥75×10∧9/L;&#xD;
&#xD;
               4. Serum alanine transaminase (SGPT/ALT) &lt; 2 x upper limit of normal (ULN)&#xD;
&#xD;
               5. Serum aspartate transaminase (SGOT/AST) &lt; 2 x ULN&#xD;
&#xD;
               6. Bilirubin (total) &lt;2.5 x ULN unless Gilbert's disease is present or subject is&#xD;
                  receiving atazanavir in the absence of other evidence of significant liver&#xD;
                  disease&#xD;
&#xD;
               7. Creatinine ≤1.5 x ULN&#xD;
&#xD;
          7. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered&#xD;
             not clinically significant by the Principal Investigator.&#xD;
&#xD;
          8. Both male and female patients and their partners of childbearing potential must agree&#xD;
             to use accepted methods of contraception.&#xD;
&#xD;
          9. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening visit and negative urine pregnancy test prior to receiving the first dose of&#xD;
             study drug.&#xD;
&#xD;
         10. Subjects who have two or more potential alternative antiretroviral treatment regimens.&#xD;
&#xD;
         11. Willing and able to participate in all aspects of the study, including use of IV&#xD;
             medication, completion of evaluations, attendance at scheduled clinic visits, and&#xD;
             compliance with all protocol requirements as evidenced by providing written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any active infection or malignancy requiring acute therapy.&#xD;
&#xD;
          2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen&#xD;
             (HBsAg).&#xD;
&#xD;
          3. Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA&#xD;
             assay at the time of screening.&#xD;
&#xD;
          4. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant&#xD;
             during the study&#xD;
&#xD;
          5. Unexplained fever or clinically significant illness within 1 week prior to the first&#xD;
             study dose&#xD;
&#xD;
          6. Any vaccination within 2 weeks prior to the first study dose.&#xD;
&#xD;
          7. Subjects BMI&lt;20 or &gt;27 kg/m∧2 [BMI＝weight/height∧2].&#xD;
&#xD;
          8. History of Bleeding Disorder or patients on anti-coagulant therapy&#xD;
&#xD;
          9. Participation in an experimental drug trial(s) within 30 days of the Screening Visit&#xD;
&#xD;
         10. Any known allergy or antibodies to the study drug or excipients&#xD;
&#xD;
         11. Treatment with any of the following:&#xD;
&#xD;
               1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit&#xD;
&#xD;
               2. Receipt of any fusion inhibitor and monoclonal antibody therapy of any kind in&#xD;
                  the past.&#xD;
&#xD;
               3. Immunosuppressants within 60 days prior to the Screening Visit&#xD;
&#xD;
               4. Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or&#xD;
                  foscarnet within 60 days prior to the screening visit&#xD;
&#xD;
               5. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit.&#xD;
                  Subjects on chronic steroid therapy &gt; 5 mg/day will be excluded with the&#xD;
                  following exception:&#xD;
&#xD;
               6. Subjects on inhaled, nasal, or topical steroids will not be excluded&#xD;
&#xD;
         12. Any other clinical condition that, in the Investigator's judgment, would potentially&#xD;
             compromise study compliance or the ability to evaluate safety/efficacy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Yao</last_name>
    <role>Study Director</role>
    <affiliation>Frontier Biotechnologies Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingxiang Xu</last_name>
    <phone>025-69648410</phone>
    <email>xxxu@frontierbiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng Yao</last_name>
    <email>yaocheng@frontierbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Taisheng Li, M.D.</last_name>
      <email>litsh@263.net</email>
    </contact>
    <investigator>
      <last_name>Taisheng Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

